White Blood Cell News and Research

RSS

Study confirms anti-inflammatory properties of Oligonol in humans

A recently published study in Nutrition Research and Practice has verified the anti-inflammatory effects in humans of Oligonol® lychee fruit polyphenol. The study examined Oligonol intake on cortisol and related cytokines in healthy young men. Both cortisol and cytokine concentrations are inflammatory markers known to increase when stress such as exercise is caused on the body.

15 Feb 2011

Cholesterol efflux capacity may protect against heart disease: Study

The discovery that high levels of high-density lipoprotein cholesterol are associated with reduced risk of cardiovascular disease has fostered intensive research to modify HDL levels for therapeutic gain. However, recent findings have called into question the notion that pharmacologic increases in HDL cholesterol levels are necessarily beneficial to patients.

4 Feb 2011

Study: Removal of B lymphocytes can reverse aging process

Researchers at the Technion-Israel Institute of Technology have discovered a way to reverse the aging process by removing old B lymphocytes from old mice, and forcing the production of young, potent cells to replace them.

27 Jan 2011

Senesco files SNS01-T IND for treatment of multiple myeloma

Senesco Technologies, Inc. today announced that the Company has filed an Investigational New Drug application with the U.S. Food and Drug Administration for Senesco's lead drug candidate SNS01-T for treatment of multiple myeloma.

24 Jan 2011

Breakthrough in understanding mechanisms behind hereditary alpha-1-antitrypsin deficiency

Researchers from the Royal College of Surgeons in Ireland (RCSI) and Beaumont Hospital have made a breakthrough in understanding the mechanisms behind the most severe form of hereditary emphysema and how protein treatments can improve the condition. The findings of this study may also lead to new treatments for patients with smoker's emphysema.

24 Jan 2011

Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis

Raptor Pharmaceutical Corp., today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

24 Jan 2011

Clinical studies by expert HIV clinicians suggest that HIV-TRePS may have clinical and economic benefits

Two multinational clinical studies indicate that the RDI’s system for predicting how HIV and AIDS patients will respond to different drugs could be a useful tool with potential clinical and economic benefits. The studies, published in the January issue of AIDS Patient Care and STDs, involved highly experienced physicians in the USA, Canada and Italy who used the system to help them select the optimum combination of HIV drugs for patients whose therapy was failing.

18 Jan 2011

Cholesterol efflux capacity is more closely associated with protection against heart disease: Study

The discovery that high levels of high-density lipoprotein cholesterol is associated with reduced risk of cardiovascular disease has fostered intensive research to modify HDL levels for therapeutic gain. However, recent findings have called into question the notion that pharmacologic increases in HDL cholesterol levels are necessarily beneficial to patients.

13 Jan 2011

Analysis of medical database reveals new diagnostic markers for allergic disorders

Researchers at the University of Gothenburg, Sweden, have developed new methods for analysing medical databases that can be used to identify diagnostic markers more quickly and to personalise medication for allergic disorders. They could also reduce the need for animal trials in clinical studies.

12 Jan 2011

New mechanisms of resistance to chemotherapy among leukemia patients

The interplay between a major tumor-suppressing gene, a truncated chromosome and two sets of microRNAs provides a molecular basis for explaining the less aggressive form of chronic lymphocytic leukemia, an international team of researchers reports today in the Jan. 4 edition of the Journal of the American Medical Association.

10 Jan 2011

FDA grants orphan drug status for Senesco's SNS01-T in treatment of multiple myeloma

Senesco Technologies, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's lead drug candidate SNS01-T for treatment of multiple myeloma.

3 Jan 2011

Researchers present definitive explanation of how fibrotic cells destroy human liver

In the latest of a series of related papers, researchers at the University of California, San Diego School of Medicine, with colleagues in Austria and elsewhere, present a new and more definitive explanation of how fibrotic cells form, multiply and eventually destroy the human liver, resulting in cirrhosis. In doing so, the findings upend the standing of a long-presumed marker for multiple fibrotic diseases and reveal the existence of a previously unknown kind of inflammatory white blood cell.

21 Dec 2010

Laparoscopic approach still best for most patients, not for all: Study

If skin is the body's fortress against germ invaders, shouldn't minimally invasive surgeries - operations guided by camera probes, conducted entirely within the abdomen - carry less risk for serious infection than procedures that slice the same cavity wide open?

9 Dec 2010

John Theurer Cancer Center presents research findings at ASH meeting

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings presented at the annual meeting of the American Society of Hematology taking place December 4-7, 2010 in Orlando, Florida. The ASH meeting is the world's leading scientific gathering of hematologists and hematology researchers.

7 Dec 2010

No overall cancer risk in people who donate stem cells

American Society of Hematology reveals that there is no increase in overall cancer risk in people who donate stem cells and that the utilization of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias.

7 Dec 2010

Mayo Clinic scientists say JAK inhibitors may help treat patients with myelofibrosis

Two janus kinase (JAK) inhibitors are substantially improving treatment of myelofibrosis in patients, say Mayo Clinic researchers who are presenting results of several clinical trials at the 52nd annual meeting of the American Society of Hematology (ASH) Dec. 4 in Orlando.

7 Dec 2010

Research reveals new standard treatment options for various forms of lymphoma

The next generation of drug therapies and enhanced treatment approaches for various forms of lymphoma are evolving as researchers continue to better understand how these cancers progress. Research will be presented today at the 52nd Annual Meeting of the American Society of Hematology introducing promising new options for the standard treatment of advanced asymptomatic follicular lymphoma, mantle cell lymphoma, and early, unfavorable (referring to patients with clinical stage I or II disease and one or more risk factors) Hodgkin disease.

6 Dec 2010

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Results from four innovative studies help answer outstanding questions about stem cell transplant procedures in treating various hematologic malignancies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology reveals that there is no increase in overall cancer risk in people who donate stem cells and that the utilization of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias.

6 Dec 2010

Lipids react and change to bacterial stimulus, trigger cell's immune response

For the first time, scientists have described not only the identities and quantities of fat species in a living mammalian cell in this case, a mouse macrophage or white blood cell but they also report how these lipids react and change over time to a bacterial stimulus triggering the cell's immune response.

2 Dec 2010

Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a phase I trial of INK128, a novel, orally-available small molecule kinase inhibitor of the TORC1 and TORC2 complexes, in patients with multiple myeloma.

30 Nov 2010

White Blood Cell News and Research

Study confirms anti-inflammatory properties of Oligonol in humans

Cholesterol efflux capacity may protect against heart disease: Study

Study: Removal of B lymphocytes can reverse aging process

Senesco files SNS01-T IND for treatment of multiple myeloma

Breakthrough in understanding mechanisms behind hereditary alpha-1-antitrypsin deficiency

Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis

Clinical studies by expert HIV clinicians suggest that HIV-TRePS may have clinical and economic benefits

Cholesterol efflux capacity is more closely associated with protection against heart disease: Study

Analysis of medical database reveals new diagnostic markers for allergic disorders

New mechanisms of resistance to chemotherapy among leukemia patients

FDA grants orphan drug status for Senesco's SNS01-T in treatment of multiple myeloma

Researchers present definitive explanation of how fibrotic cells destroy human liver

Laparoscopic approach still best for most patients, not for all: Study

John Theurer Cancer Center presents research findings at ASH meeting

No overall cancer risk in people who donate stem cells

Mayo Clinic scientists say JAK inhibitors may help treat patients with myelofibrosis

Research reveals new standard treatment options for various forms of lymphoma

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Lipids react and change to bacterial stimulus, trigger cell's immune response

Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma

Immunology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News